Author Contributions Conceived and designed the experiments: WWD BBY AS AJY. Performed the experiments: WWD AJY BLY ZD ZJ SWS. Analyzed the data: WWD References 1. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN (1999) Chemo- signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 25: 271–277. 2. Flowers M, Thompson PA (2009) t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2. PLoS One 4: e5342. 3. Xu J, Zhou JY, Wei WZ, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226. 4. Boldt S, Weidle UH, Kolch W (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831–1838. 5. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R (2004) The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. Faseb J 18: 779–781. 6. Kaufmann SH (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 195–211. 7. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, et al. (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67: 4742–4750. 8. Wu Y, Wu J, Lee DY, Yee A, Cao L, et al. (2005) Versican protects cells from oxidative stress-induced apoptosis. Matrix Biol 24: 3–13. 9. Yamaguchi Y (2000) Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 57: 276–289. 10. Zimmermann DR, Ruoslahti E (1989) Multiple domains of the large fibroblast proteoglycan, versican. Embo J 8: 2975–2981. 11. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, et al. (2004) Versican/PG- M G3 domain promotes tumor growth and angiogenesis. Faseb J 18: 754–756. 12. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB (2005) The interaction of versican with its binding partners. Cell Res 15: 483–494. 13. Zheng PS, Vais D, Lapierre D, Liang YY, Lee V, et al. (2004) PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 117: 5887–5895. 14. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4: e8461. 15. Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, et al. (1997) Immunohisto- chemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 29: 21–30. 16. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, et al. (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8: 1054–1060. 17. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, et al. (1998) Elevated levels of versican but not decorin predict disease progression in early- stage prostate cancer. Clin Cancer Res 4: 963–971. 18. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, et al. (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node- negative breast cancer. Clin Cancer Res 10: 2491–2498. 19. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, et al. (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9: R47. 20. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, et al. (2010) Versican G3 Promotes Mouse Mammary Tumor Cell Growth, Migration, and Metastasis by Influencing EGF Receptor Signaling. PLoS ONE 5(11): e13828. doi: 10.1371/ journal.pone.0013828. 21. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, et al. (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3: e2881. 22. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263–1284. 23. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, et al. (2006) Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483–3492. 24. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, et al. (2010) Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 5: e10767. 25. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, et al. (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4: e7181. 26. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399–1405. 27. Walker-Nasir E, Codington JF, Jahnke MR, Fuller TC, Jeanloz RW (1982) Isolation and partial characterization of surface components of cell line MDA- MB-231 derived from a human metastatic breast carcinoma. J Natl Cancer Inst 69: 371–380. Versican G3 Modulates Breast Cancer Cell Apoptosis AJY. Contributed reagents/materials/analysis tools: WWD AJY LF ZJ YZ. Wrote the paper: WWD AJY. 28. Hambly RJ, Double JA, Thompson MJ, Bibby MC (1997) Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Breast Cancer Res Treat 43: 247–258. 29. Horwitz KB, Costlow ME, McGuire WL (1975) MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26: 785–795. 30. Buick RN, Filmus J, Church J (1990) Studies of EGF-mediated growth control and signal transduction using the MDA-MB-468 human breast cancer cell line. Prog Clin Biol Res 354A: 179–191. 31. Zhang Y, Cao L, Yang BL, Yang BB (1998) The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 273: 21342–21351. 32. Wu Y, Zhang Y, Cao L, Chen L, Lee V, et al. (2001) Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 276: 14178–14186. 33. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, et al. (2000) Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif. J Biol Chem 275: 21255–21261. 34. Chen L, Wu Y, Lee V, Kiani C, Adams ME, et al. (2002) The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion. J Biol Chem 277: 2657–2665. 35. Kiani C, Lee V, Cao L, Chen L, Wu Y, et al. (2001) Roles of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 354: 199–207. 36. Kahai S, Lee SC, Lee DY, Yang J, Li M, et al. (2009) MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One 4: e7535. 37. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, et al. (2009) MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 11: 1031–1038. 38. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, et al. (2008) MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One 3: e2420. 39. Lee DY, Deng Z, Wang CH, Yang BB (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 104: 20350–20355. 40. Lyseng-Williamson KA, Fenton C (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65: 2513–2531. 41. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36: 99–114. 42. Schabel FM, Jr. (1977) Rationale for adjuvant chemotherapy. Cancer 39: 2875–2882. 43. Brock N (1996) The history of the oxazaphosphorine cytostatics. Cancer 78: 542–547. 44. Schaller G, Bangemann N, Becker C, Buhler H, Opri F, et al. (1999) Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 125: 520–524. 45. Filmus J, Pollak MN, Cailleau R, Buick RN (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898–905. 46. Wu Y, Chen L, Cao L, Sheng W, Yang BB (2004) Overexpression of the C- terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 117: 2227–2237. 47. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, et al. (2006) Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 17: 2009–2020. 48. Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z, et al. (2009) A 39- untranslated region (39UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One 4: e4527. 49. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550–6565. 50. Prenzel N, Zwick E, Leserer M, Ullrich A (2000) Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2: 184–190. 51. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, et al. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041–1056. 52. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937–947. 53. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, et al. (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase PLoS ONE | www.plosone.org 14 November 2011 | Volume 6 | Issue 11 | e26396